FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Wei XuJianqing Wu

Abstract

Fibroblast growth factor receptor 4 (FGFR4), belonging to the receptor tyrosine kinase family, is involved in cancer initiation and progression. The FGFR4 Gly388Arg polymorphism in the transmembrane domain of the receptor was shown to contribute to genetic susceptibility to cancer but the results were inconsistent. We performed a meta-analysis using 12 eligible case-control studies with a total of 4892 patients and 3663 controls to summarise the data on the association between the FGFR4 Gly388Arg polymorphism and cancer risks. The overall odds ratio (OR) with a 95% confidence interval (CI) showed statistical association between the FGFR4 Gly388Arg polymorphism and cancer risks under homozygote comparison, allele contrast and the recessive genetic model. In the subgroup analysis by ethnicity, statistically significantly increased cancer risks were found among Asians for homozygote comparison (OR = 1.43, 95% CI = 1.13-1.80, P(heterogeneity)=0.24), allele contrast (OR = 1.16, 95% CI = 1.04-1.29, P(heterogeneity) = 0.25) and the recessive genetic model (OR = 1.47, 95% CI = 1.19-1.81, P(heterogeneity) = 0.15). In the subgroup analysis for different tumour types, Arg(388) allele had an effect of increasing the risks of breast (homozy...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Dec 1, 1994·International Journal of Cancer. Journal International Du Cancer·H Y LeungN R Lemoine
May 28, 1993·International Journal of Cancer. Journal International Du Cancer·S JaakkolaH Nevanlinna
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Apr 20, 1999·Biochemical and Biophysical Research Communications·A TakahashiT Tsukamoto
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·S RaffioniR A Bradshaw
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Oct 6, 2000·Endocrine-related Cancer·C J PowersA Wellstein
Jun 16, 2004·International Journal of Cancer. Journal International Du Cancer·Sylvia StreitAxel Ullrich
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jianghua WangMichael Ittmann
Dec 23, 2004·Endocrine-related Cancer·B Kwabi-AddoM Ittmann
May 3, 2005·Cytokine & Growth Factor Reviews·V P EswarakumarJ Schlessinger
Aug 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monica SpinolaTommaso A Dragani
Jul 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph ThussbasNadia Harbeck
Nov 7, 2006·Experimental and Molecular Pathology·Valéria Cristina da Costa AndradeBernardo Garicochea
Jul 4, 2007·The Journal of Pathology·K SahadevanV J Gnanapragasam
Sep 3, 2008·Prostate Cancer and Prostatic Diseases·L M FitzGeraldE A Ostrander
Mar 20, 2009·International Journal of Cancer. Journal International Du Cancer·Felicia S FalvellaTommaso A Dragani
Nov 18, 2009·Prostate Cancer and Prostatic Diseases·C K M HoF K Habib

❮ Previous
Next ❯

Citations

Aug 1, 2013·Apoptosis : an International Journal on Programmed Cell Death·Kai Hung TiongChee-Onn Leong
Aug 23, 2012·Breast Cancer Research and Treatment·Khyber Saify, Mostafa Saadat
Apr 24, 2012·Carcinogenesis·Ernest K AmankwahJong Y Park
Aug 1, 2013·World Journal of Gastroenterology : WJG·Yan-Ying ShenXing-Zhi Ni
Jan 7, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Clarissa A CassolSylvia L Asa
Sep 2, 2011·Molecular Carcinogenesis·Amy D MarshallGerard C Grosveld
May 16, 2015·International Journal of Cancer. Journal International Du Cancer·Dorota ButkiewiczRafał Suwiński
Apr 22, 2015·Cellular and Molecular Life Sciences : CMLS·Sami BenzinaXavier Gidrol
Jun 30, 2011·The Biochemical Journal·Jørgen WescheEllen Margrethe Haugsten
Aug 30, 2013·Acta Biochimica Et Biophysica Sinica·Jing HuangTao Zhang
Dec 5, 2012·The Journal of International Medical Research·H F ZhangQ H Huang
Feb 4, 2016·Journal of Pediatric Hematology/oncology·Sarah B WhittlePeter E Zage
Mar 11, 2020·Frontiers in Cell and Developmental Biology·Yanan LiuRi Cui
Jun 7, 2019·Cells·Aroosha RajaSung-Min Ahn
May 13, 2020·BMC Medical Genetics·Warren A ChowSherri Z Millis
Jun 1, 2011·Molecular and Cellular Biochemistry·Anna P BatschauerKarina B Gomes
Aug 13, 2020·International Journal of Environmental Research and Public Health·Ju-Pi LiShun-Fa Yang
Jan 16, 2021·Scientific Reports·Tao PengYuanyuan Mi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.